The classic website will no longer be available as of June 25, 2024. Please use the modernized ClinicalTrials.gov.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    BBI-20201001
Previous Study | Return to List | Next Study

A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04278144
Recruitment Status : Recruiting
First Posted : February 20, 2020
Last Update Posted : February 29, 2024
Sponsor:
Collaborator:
Bristol-Myers Squibb
Information provided by (Responsible Party):
Bolt Biotherapeutics, Inc.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
A first-in-human study using BDC-1001 as a single agent and in combination with nivolumab in HER2 expressing advanced malignancies

Condition or disease Intervention/treatment Phase
HER2-positive Solid Tumors HER2-positive Breast Cancer HER2-positive Colorectal Cancer HER2-positive Gastroesophageal Cancer HER2-positive Endometrial Cancer Drug: BDC-1001 Drug: Nivolumab Phase 1 Phase 2

Detailed Description:
This study has four parts. Part 1 is a dose escalation of BDC-1001 as a single agent to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), or maximum protocol dose (MPD) recommended for Part 3. In Part 3, the selected dose will be administered as monotherapy to patients with selected advanced malignancies. Part 2 is a dose escalation of BDC-1001 in combination with nivolumab to determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D), or maximum protocol dose (MPD) recommended for Part 4. In Part 4, the selected dose will be administered in combination with nivolumab to patients with selected advanced malignancies.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 390 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multiple ascending dose and dose-expansion of BDC-1001 administered as a single agent or in combination with nivolumab.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Phase 1/2 Study of BDC-1001 as a Single Agent and in Combination With Nivolumab in Patients With Advanced HER2-Expressing Solid Tumors
Actual Study Start Date : February 24, 2020
Estimated Primary Completion Date : January 31, 2025
Estimated Study Completion Date : October 31, 2026

Resource links provided by the National Library of Medicine

Drug Information available for: Nivolumab

Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Single agent BDC-1001
Escalating doses followed by expansion targeting HER2-expressing advanced malignancies
 Drug: BDC-1001
Immune stimulating antibody conjugate (ISAC), consisting of an anti-HER2 monoclonal antibody conjugated to a TLR 7/8 dual agonist
Experimental: Combination BDC-1001 plus nivolumab
Escalating doses followed by expansion targeting HER2-expressing advanced malignancies
 Drug: BDC-1001
Immune stimulating antibody conjugate (ISAC), consisting of an anti-HER2 monoclonal antibody conjugated to a TLR 7/8 dual agonist

Drug: Nivolumab
Programmed death receptor-1 (PD 1)-blocking antibody
Other Name: Opdivo


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Incidence of adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: 2 years ]
    Escalation period

  2. Incidence and nature of dose-limiting toxicities (DLTs) [ Time Frame: up to 21 days ]
    Escalation period

  3. Incidence of potential-immune related toxicities [ Time Frame: 2 years ]
    Escalation period

  4. Maximum tolerable dose (MTD) or a tolerated dose below MTD [ Time Frame: 2 years ]
    Escalation period

  5. Objective response rate (ORR) of confirmed complete or partial responses (CR, PR) [ Time Frame: 2 years ]
    Expansion period


Secondary Outcome Measures :
  1. PK (Cmax) of BDC-1001 [ Time Frame: 2 years ]
    Escalation and expansion periods

  2. PK (Cmin) of BDC-1001 [ Time Frame: 2 years ]
    Escalation and expansion periods

  3. PK (AUC0-t) of BDC-1001 [ Time Frame: 2 years ]
    Escalation period

  4. PK (AUC0-inf) of BDC-1001 [ Time Frame: 2 years ]
    Escalation period

  5. PK (CL) of BDC-1001 [ Time Frame: 2 years ]
    Escalation period

  6. PK (Vz) of BDC-1001 [ Time Frame: 2 years ]
    Escalation period

  7. PK (t1/2) of BDC-1001 [ Time Frame: 2 years ]
    Escalation period

  8. Objective response rate (ORR) using RECIST 1.1 [ Time Frame: 2 years ]
    Escalation period

  9. Duration of response (DOR) [ Time Frame: 2 years ]
    Escalation and expansion periods

  10. Disease control rate (DCR) of confirmed CR, PR, or stable disease (SD) lasting 4 or more weeks [ Time Frame: 2 years ]
    Escalation and expansion periods

  11. Progression Free Survival (PFS) [ Time Frame: 2 years ]
    Escalation and expansion periods

  12. Incidence of anti-BDC-1001 antibodies [ Time Frame: 2 years ]
    Escalation and expansion periods

  13. Incidence of adverse events (AEs) and serious adverse events (SAEs) [ Time Frame: 2 years ]
    Expansion period

  14. Incidence of potential-immune related toxicities [ Time Frame: 2 years ]
    Expansion period


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Key Inclusion Criteria:

  • Patient must have an advanced solid tumor with documented HER2-protein expression or gene amplification for which approved therapies have been exhausted or are not clinically indicated.
  • Measurable disease as determined by RECIST v.1.1.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
  • Tumor tissue (archival or collected prior to the study start) available for exploratory biomarker evaluation.

Key Exclusion Criteria:

  • History of severe hypersensitivity to any ingredient of the study drug(s), including trastuzumab or other monoclonal antibody.
  • Previous treatment with a TLR 7, TLR 8 or a TLR 7/8 agonist.
  • Impaired cardiac function or history of clinically significant cardiac disease
  • Human Immunodeficiency virus (HIV) infection, active hepatitis B infection, or hepatitis C infection.
  • Active SARS-CoV-2 infection
  • Untreated central nervous system (CNS), epidural tumor or metastasis, or brain metastasis.

Other protocol defined inclusion/exclusion criteria may apply.

Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04278144


Contacts
Layout table for location contacts
Contact: Bolt Biotherapeutics +1 650 434 8640 clinicaltrials@boltbio.com

Locations
Show Show 23 study locations
Sponsors and Collaborators
Bolt Biotherapeutics, Inc.
Bristol-Myers Squibb
Investigators
Layout table for investigator information
Study Director: Bolt Clinical Development Bolt Biotherapeutics
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Bolt Biotherapeutics, Inc.
ClinicalTrials.gov Identifier: NCT04278144    
Other Study ID Numbers: BBI-20201001
First Posted: February 20, 2020    Key Record Dates
Last Update Posted: February 29, 2024
Last Verified: February 2023

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Bolt Biotherapeutics, Inc.:
HER2
ERBB2
Immunotherapy
Gastric Cancer
Gastroesophageal junction
Breast Cancer
Stomach Cancer
Colorectal Cancer
 Gastrointestinal Cancer
Non-Small Cell Lung Cancer
Biliary Tract Cancer
Head and Neck Cancer
Urothelial Cancer
Endometrial Cancer
TLR7/8 agonist
Additional relevant MeSH terms:
Layout table for MeSH terms
Colorectal Neoplasms
Endometrial Neoplasms
Neoplasms by Site
Neoplasms
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Digestive System Diseases
Gastrointestinal Diseases
Colonic Diseases
Intestinal Diseases
Rectal Diseases
Uterine Neoplasms
 Genital Neoplasms, Female
Urogenital Neoplasms
Uterine Diseases
Genital Diseases, Female
Female Urogenital Diseases
Female Urogenital Diseases and Pregnancy Complications
Urogenital Diseases
Genital Diseases
Nivolumab
Antineoplastic Agents, Immunological
Antineoplastic Agents
Immune Checkpoint Inhibitors
Molecular Mechanisms of Pharmacological Action